Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
2.020
+0.020 (1.00%)
At close: May 15, 2025, 4:00 PM
2.040
+0.020 (0.99%)
After-hours: May 15, 2025, 6:36 PM EDT
Compass Therapeutics Employees
Compass Therapeutics had 35 employees as of December 31, 2024. The number of employees increased by 3 or 9.38% compared to the previous year.
Employees
35
Change (1Y)
3
Growth (1Y)
9.38%
Revenue / Employee
$24,286
Profits / Employee
-$1,577,743
Market Cap
279.33M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 35 | 3 | 9.38% |
Dec 31, 2023 | 32 | 6 | 23.08% |
Dec 31, 2022 | 26 | 2 | 8.33% |
Dec 31, 2021 | 24 | -7 | -22.58% |
Dec 31, 2020 | 31 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CMPX News
- 3 days ago - Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers - Seeking Alpha
- 7 days ago - Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - Compass Therapeutics to Participate in Upcoming May Investor Events - GlobeNewsWire
- 17 days ago - Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 24 days ago - Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer - GlobeNewsWire
- 6 weeks ago - Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - GlobeNewsWire
- 6 weeks ago - Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - GlobeNewsWire
- 6 weeks ago - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer - GlobeNewsWire